Research Use Only
This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.
Cagrilintide
Metabolic & Weight LossPhase 3Also known as: NN9838
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. Currently in Phase 3 trials as the combination CagriSema (cagrilintide + semaglutide) for obesity treatment.
Overview
Key Takeaways
- →Weight loss
- →Appetite suppression (via different pathway than GLP-1)
- →Glucagon suppression
At A Glance
Cagrilintide binds amylin receptors (AMY1R, AMY2R, AMY3R), which are expressed widely in the hypothalamus, brainstem, and reward circuits. Amylin receptor activation reduces food intake through complementary mechanisms to GLP-1: it slows gastric emptying, reduces glucagon secretion, and suppresses appetite through area postrema and nucleus tractus solitarius signaling. The fatty acid acylation provides a plasma half-life of approximately 7 days — similar to semaglutide, enabling once-weekly co-dosing.
Cagrilintide binds amylin receptors (AMY1R, AMY2R, AMY3R), which are expressed widely in the hypothalamus, brainstem, and reward circuits. Amylin receptor activation reduces food intake through complementary mechanisms to GLP-1: it slows gastric emptying, reduces glucagon secretion, and suppresses appetite through area postrema and nucleus tractus solitarius signaling. The fatty acid acylation provides a plasma half-life of approximately 7 days — similar to semaglutide, enabling once-weekly co-dosing.
Overview
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. Currently in Phase 3 trials as the combination CagriSema (cagrilintide + semaglutide) for obesity treatment. Phase 2 CagriSema trials showed approximately 15.6% weight loss at 32 weeks with the combination — superior to either agent alone — suggesting complementary mechanisms across GLP-1 and amylin pathways.
Potential Benefits
Potential Research Fields
Chemical Information
IUPAC Name
Amylin analog with N-terminal fatty acid acylation (proprietary)
CAS Number
2172366-25-3
Molecular Formula
C195H286N46O60
Molecular Mass
4246.7 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Create a free account to:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
Join 2,800+ researchers
Research
Unlock Research Data
Create a free account to:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
Join 2,800+ researchers
Interactions
Interaction Matrix
Contraindications
Pregnancy or breastfeeding. Diabetes (affects glucose metabolism). Hormone-sensitive cancers.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$49.99
up to $79.99
$7.9990
3
3
vial
Related Compounds
View AllAOD-9604
Metabolic & Weight Loss
AOD-9604 is a modified 16-amino acid fragment of the C-terminal region of human growth hormone (residues 176-191) with an additional tyrosine at the N-terminus and a disulfide bond.
HGH Fragment 176-191
Metabolic & Weight Loss
HGH Fragment 176-191 is a stabilized peptide fragment of the C-terminus of human growth hormone, corresponding to amino acids 176–191 with a tyrosine addition at the N-terminus.
Retatrutide
Metabolic & Weight Loss
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly targeting GLP-1, GIP, and glucagon receptors simultaneously.
Semaglutide
Metabolic & Weight Loss
Semaglutide is a GLP-1 receptor agonist with 94% amino acid sequence homology to native human GLP-1.
Tirzepatide
Metabolic & Weight Loss
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023).
View Full Dosage Guide →
Protocols, calculator & safety for Cagrilintide
Research Score
43 PubMed studies
Quality Indicators
Data Completeness
88%COA Verification
10
Verified COAs
2
Vendors w/ COA
High verification rate (83%)
Latest test: 3/1/2026
Research Credibility
Quick Facts
Molecular Weight
4246.7 g/mol
CAS Number
2172366-25-3
Trial Phase
Phase 3
Safety Profile
Moderate RiskCommon Side Effects
- • Nausea
- • Vomiting
- • Decreased appetite
- • Injection site reactions
Stop Use If
- Phase 3 trials ongoing — long-term safety profile incomplete
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is Cagrilintide used for in research?
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. Currently in Phase 3 trials as the combination CagriSema (cagrilintide + semaglutide) for obesity treatment. Phase 2 CagriSema trials showed approximately 15.6% weight loss at 32 weeks with the combination — superior to either agent alone — suggesting complementary mechanisms across GLP-1 and amylin pathways.
What forms does Cagrilintide come in?
Cagrilintide is available in vial form.
How much does Cagrilintide cost?
Prices start at $49.99 across 3 verified vendors.
How do I compare Cagrilintide vendors?
Compare prices, payment methods, shipping, and COA scores across 3 vendors.
Research Tools
Related Compounds
View AllAOD-9604
Metabolic & Weight Loss
AOD-9604 is a modified 16-amino acid fragment of the C-terminal region of human growth hormone (residues 176-191) with an additional tyrosine at the N-terminus and a disulfide bond.
HGH Fragment 176-191
Metabolic & Weight Loss
HGH Fragment 176-191 is a stabilized peptide fragment of the C-terminus of human growth hormone, corresponding to amino acids 176–191 with a tyrosine addition at the N-terminus.
Retatrutide
Metabolic & Weight Loss
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly targeting GLP-1, GIP, and glucagon receptors simultaneously.
Semaglutide
Metabolic & Weight Loss
Semaglutide is a GLP-1 receptor agonist with 94% amino acid sequence homology to native human GLP-1.
Tirzepatide
Metabolic & Weight Loss
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023).